Pharmacosmos tight-lipped on competitor's Chinese market nod
CSL Vifor has just won Chinese approval of Ferinject, an IV iron deficiency drug. ”We have always had the assumption baked into our plans that they would be approved at some point,” says Tobias S. Christensen, the CEO of Pharmacosmos.
by ulrich qustgaard, translated by daniel pedersen
Competition on the Chinese market for intravenous (IV) iron deficiency treatments is heating up after CSL Vifor, previously known as Vifor Pharma, has had a drug in the indication, Ferinject, approved in the country.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
China approves Vifor's iron deficiency IV infusion
For subscribers
Pharmacosmos expects massive growth in four years
For subscribers
